These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21136867)

  • 1. MicroRNA and proteome expression profiling in early-symptomatic α-synuclein(A30P)-transgenic mice.
    Gillardon F; Mack M; Rist W; Schnack C; Lenter M; Hildebrandt T; Hengerer B
    Proteomics Clin Appl; 2008 May; 2(5):697-705. PubMed ID: 21136867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
    Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
    Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
    Marxreiter F; Nuber S; Kandasamy M; Klucken J; Aigner R; Burgmayer R; Couillard-Despres S; Riess O; Winkler J; Winner B
    Eur J Neurosci; 2009 Mar; 29(5):879-90. PubMed ID: 19291219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein A30P decreases neurodegeneration and increases synaptic vesicle release probability in CSPα-null mice.
    Ruiz R; Biea IA; Tabares L
    Neuropharmacology; 2014 Jan; 76 Pt A():106-17. PubMed ID: 24036317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
    Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
    Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olfactory neuron-specific expression of A30P α-synuclein exacerbates dopamine deficiency and hyperactivity in a novel conditional model of early Parkinson's disease stages.
    Nuber S; Petrasch-Parwez E; Arias-Carrión O; Koch L; Kohl Z; Schneider J; Calaminus C; Dermietzel R; Samarina A; Boy J; Nguyen HP; Teismann P; Velavan TP; Kahle PJ; von Hörsten S; Fendt M; Krüger R; Riess O
    Neurobiol Dis; 2011 Nov; 44(2):192-204. PubMed ID: 21767644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
    Matsuoka Y; Vila M; Lincoln S; McCormack A; Picciano M; LaFrancois J; Yu X; Dickson D; Langston WJ; McGowan E; Farrer M; Hardy J; Duff K; Przedborski S; Di Monte DA
    Neurobiol Dis; 2001 Jun; 8(3):535-9. PubMed ID: 11442360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-10a inhibits A30P α-synuclein aggregation and toxicity by targeting proapoptotic protein BCL2L11.
    Liang H; Ding B; Liang J; Shi X; Jiang X; Gao Y
    Int J Clin Exp Pathol; 2018; 11(2):624-633. PubMed ID: 31938148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein array analysis of oligomerization-induced changes in alpha-synuclein protein-protein interactions points to an interference with Cdc42 effector proteins.
    Schnack C; Danzer KM; Hengerer B; Gillardon F
    Neuroscience; 2008 Jul; 154(4):1450-7. PubMed ID: 18541383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.
    Moussa CE; Wersinger C; Tomita Y; Sidhu A
    Biochemistry; 2004 May; 43(18):5539-50. PubMed ID: 15122920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity.
    Smith WW; Jiang H; Pei Z; Tanaka Y; Morita H; Sawa A; Dawson VL; Dawson TM; Ross CA
    Hum Mol Genet; 2005 Dec; 14(24):3801-11. PubMed ID: 16239241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
    Ono K; Ikemoto M; Kawarabayashi T; Ikeda M; Nishinakagawa T; Hosokawa M; Shoji M; Takahashi M; Nakashima M
    Parkinsonism Relat Disord; 2009 Nov; 15(9):649-54. PubMed ID: 19345133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein.
    Rockenstein E; Schwach G; Ingolic E; Adame A; Crews L; Mante M; Pfragner R; Schreiner E; Windisch M; Masliah E
    J Neurosci Res; 2005 Apr; 80(2):247-59. PubMed ID: 15765523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
    Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
    Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.